Create Account | Sign In: Author or Forum

Search Symptoms

Category: Internal Medicine | Nephrology | Journal

Back to Journal Articles

New Test May Predict Risk of End-Stage Renal Disease

Last Updated: April 13, 2009.

In the general population, estimated glomerular filtration rate and urine albumin excretion -- even in the range of microalbuminuric values -- are powerful predictors of end-stage renal disease, according to study findings published online April 8 in the Journal of the American Society of Nephrology.

MONDAY, April 13 (HealthDay News) -- In the general population, estimated glomerular filtration rate (eGFR) and urine albumin excretion -- even in the range of microalbuminuric values -- are powerful predictors of end-stage renal disease, according to study findings published online April 8 in the Journal of the American Society of Nephrology.

Stein I. Hallan, M.D., of St. Olav University Hospital in Trondheim, Norway, and colleagues analyzed data from a population-based study of 65,589 adults, 124 of whom progressed to end-stage renal disease during a 10.3-year follow-up.

The researchers found that progression to end-stage renal disease was independently associated with eGFR of 45-59, 30-44 and 15-29 (hazard ratios, 6.7, 18.8 and 65.7, respectively) and with microalbuminuria and macroalbuminuria (hazard ratios, 13 and 47.2, respectively). They also found that hypertension, diabetes, male gender, smoking, depression, obesity, cardiovascular disease, dyslipidemia, physical activity and education did not add predictive information.

"Future renal risk scores and chronic kidney disease classification systems based on these two variables will be a simple and powerful tool improving our ability to handle efficiently the large group of patients with chronic kidney disease," the authors conclude.

Abstract
Full Text


Previous: Pain Requires Meticulous Attention in Intensive Care Units Next: Low Risk of Thromboembolism Found in Podiatric Surgery

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: